13233
clinical study

Unveiling the Impact of Riverain's Vessel Suppression: Breakthrough or Bust?

Materials & Methods

This retrospective study evaluates the impact of vessel suppression on radiology residents’ reading speed and detection of ≤2mm pulmonary nodules over 14 months, before and after implementation. It includes CT chest exams for patients with malignancy risk. Reading times were measured, and final reports were analyzed using natural language processing (NLP) algorithms to assess nodule size and detection rates.

Results

A total of 4,429 CT chest scans were analyzed (1,002 pre- and 3,427 post-implementation). After vessel suppression implementation, average reading time significantly decreased from 19.1 to 12.2 minutes (p<0.01), and punctate pulmonary nodule detection increased from 13.0% to 24.2% (p<0.01).

Conclusions

Vessel suppression can enhance CT chest reading speed for radiology residents, particularly in high-risk cancer patients, while also increasing punctate nodule detection. 

Disclaimer: This links to a third-party website, which may require credentials to review. 

Explore the Latest AI Insights, Trends and Research

Daniel Spector

<p>Daniel Spector is an AI Transformation Consultant at Aidoc. His focus is enabling clinicians and hospital administrators to provide better, more efficient care through the power of AI augmentation for enterprise imaging.</p>

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>